SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
SciClone Pharmaceuticals, Inc. (SCLN) 当前追踪市盈率 (P/E) 为 19.2. 追踪盈利收益率为 5.20%. PEG 5.34.
本页证实的标准:
- VALUE (75/100, 通过) — 市盈率低于市场平均水平 (19.2); 盈利收益率超过债券收益率 (5.20%).
- PEG 比率 5.34 — 高于2.0表明相对于盈利增长偏贵。
- 追踪盈利收益率 5.20% — 超过典型债券收益率（约4.3%），使股票相对固定收益更具吸引力。
SharesGrow 综合评分： 78/100 其中 5/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
75/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — SCLN
估值倍数
P/E (TTM)19.2
前瞻 P/EN/A
PEG 比率5.34
前瞻 PEGN/A
P/B 比率0.00
P/S 比率3.66
EV/EBITDA0.0
每股数据
EPS (TTM)$0.58
每股账面价值$0.00
每股营收$3.05
每股自由现金流$0.00
收益率与内在价值
盈利收益率5.20%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2007 |
$-215.79 |
$37.06B |
$-9.95B |
-26.8% |
| 2008 |
$-180.64 |
$54.11B |
$-8.35B |
-15.4% |
| 2009 |
$0.25 |
$72.41M |
$11.95M |
16.5% |
| 2010 |
$0.43 |
$85.11M |
$21.08M |
24.8% |
| 2011 |
$0.48 |
$133.64M |
$28.46M |
21.3% |
| 2012 |
$0.16 |
$156.27M |
$9.62M |
6.2% |
| 2013 |
$0.20 |
$127.06M |
$10.96M |
8.6% |
| 2014 |
$0.48 |
$134.79M |
$25.21M |
18.7% |
| 2015 |
$0.56 |
$157.26M |
$29.46M |
18.7% |
| 2016 |
$0.58 |
$160.1M |
$30.73M |
19.2% |
